Chemotherapy-free treatment of indolent lymphomas

During the 25th Congress of the European Hematology Association (EHA), the Lymphoma Hub spoke to Emanuele Zucca, Institute of Oncology Research, Bellinzona, CH, about chemotherapy-free treatment of indolent lymphomas.

Outcomes of patients with indolent lymphoma has improved over the past couple of decades. Addition of the emerging novel agent, rituximab, to standard chemotherapy is largely responsible for this positive shift. However, there is a subset of patients that experience rapid progression and poorer outcomes. Advanced disease is treated with chemotherapy + rituximab, however rituximab alone demonstrates good clinical efficacy.

Here, Emanuele Zucca discusses the long-term data from a study investigating the role of single-agent rituximab for the treatment of follicular lymphoma.